Garcinone C

Garcinone C: A Comprehensive Reference

1. Identity and Chemical Characterization

1.1 Nomenclature and Classification

Garcinone C is a natural compound isolated from Garcinia oblongifolia Champ., and is a xanthone derivative with potential cytotoxic effects on certain cancers. It belongs to the broader class of prenylated xanthones — polycyclic aromatic polyketides bearing prenyl (isoprene-derived) side chains. Three new tetraoxygenated xanthones (garcinones A, B and C), each disubstituted with C5-units, were first isolated from the chloroform extract of the fruit-hulls of Garcinia mangostana.

The compound is assigned the following unambiguous identifiers:

• IUPAC chemical name: 1,3,6,7-tetrahydroxy-8-(3-hydroxy-3-methylbutyl)-2-(3-methylbut-2-en-1-yl)-9H-xanthen-9-one
• Molecular formula and weight: Garcinone C has the molecular formula C₂₃H₂₆O₇ and a molecular weight of 414.5.
• CAS registry number: 76996-27-5
• PubChem CID: 44159808

Structurally, xanthone (9H-xanthene-9-one) is a unique chemical structure with a dibenzo-γ-pyrone heterocyclic scaffold. Garcinone C is a tetraoxygenated member of this class, carrying four hydroxyl substituents and two C5 prenyl-type side chains — one a standard 3-methylbut-2-enyl (prenyl) group and the other a saturated 3-hydroxy-3-methylbutyl chain — at specific positions around the xanthene ring system.

1.2 Natural Sources and Botanical Origins

Garcinone C is found in multiple species of the genus Garcinia. The genus Garcinia (Clusiaceae family) is native to Asia and Africa, comprises more than 300 species that have multiple applications in culinary, pharmaceutical, and industrial fields. The Garcinia species are well recognized as a rich source of xanthone derivatives.

Its most studied and commercially relevant botanical source is the mangosteen, Garcinia mangostana L. Mangosteen (Garcinia mangostana L.) is an evergreen tropical tree belonging to the Clusiaceae family that grows in Southeast Asia, and is cultivated mainly as a source of its highly palatable fruit, consisting of a fragrant white internal pulp divided in septa, contained in a dark purple rind. It is cultivated in the tropical rainforest of some Southeast Asian nations like Indonesia, Malaysia, Sri Lanka, Philippines, and Thailand.

Within the plant, xanthones have been isolated from pericarp, whole fruit, heartwood, and leaves. The pericarp has the highest content of xanthones among all the other parts of G. mangostana. Other xanthones present in mangosteen pericarp alongside garcinone C include β-mangostin, gartanin, 8-deoxygartanin, garcinones A, B, D and E, mangostinone, 9-hydroxycalabaxanthone and isomangostin, among others. Beyond G. mangostana, garcinone C has also been specifically identified as a natural compound in Garcinia oblongifolia Champ., a related species in the same family.

1.3 Common Forms and Preparations

Garcinone C as a pure isolated compound is not itself marketed widely as a standalone dietary supplement. Rather, it is consumed as one of many xanthones in preparations derived from whole mangosteen. The seeds and pericarps of the fruit have a long history of use in the traditional medicinal practices of the region, and beverages containing mangosteen pulp and pericarps are sold worldwide as nutritional supplements. In research settings, garcinone C is produced as a high-purity reference standard isolated from pericarp extracts through column chromatographic separation of chloroform or ethyl acetate fractions. Garcinone C has been separated from the EtOAc-soluble fraction of the air-dried pericarps of Garcinia mangostana (Clusiaceae). In experimental pharmacology studies, the compound is typically dissolved in dimethyl sulfoxide (DMSO) for in vitro assays, or formulated in appropriate carriers for in vivo animal work.

2. Traditional and Historical Use

2.1 Southeast Asian Ethnomedicine

The traditional use of garcinone C cannot be separated from the broader ethnopharmacological history of Garcinia mangostana, since the compound was not isolated or identified until the modern era. The pericarp of mangosteen fruit has been used as a medicinal agent by Southeast Asians for centuries in the treatment of skin infections and wounds, as well as amoebic dysentery. People in Indonesia, Malaysia, Sri Lanka, Philippines, and Thailand have used the pericarp (peel, rind, hull or ripe) of Garcinia mangostana as a traditional medicine for the treatment of abdominal pain, diarrhea, dysentery, infected wound, suppuration, and chronic ulcer.

Early reports of the traditional uses of infusions and decoctions of its peels and seeds to treat gastrointestinal and urinary tract infections, and as anti-scorbutic, laxative and anti-fever agent, date from almost two hundred years ago. In Ayurvedic medicine the pericarp of mangosteen fruit has wide use against inflammation and diarrhea, and cholera and dysentery.

In traditional practice, the dried pericarp rind was typically prepared as a decoction (water-boiled extract), a poultice for topical application to wounds, or as a powdered preparation. The bitter pericarp is applied in traditional Southeast Asian remedies for ailments ranging from gastrointestinal issues, like abdominal pain and diarrhea, to skin conditions, such as infected wounds and chronic ulcers. The traditional use of the mangosteen pericarp in treating infected wounds and ulcers implies a role in modulating local immune responses and inflammatory processes.

2.2 Chinese Medicinal Tradition

Garcinone C is also linked to Garcinia oblongifolia, which has a documented place in Chinese traditional medicine. As a natural compound extracted from Garcinia oblongifolia Champ., garcinone C is used as an anti-inflammatory, analgesia, astringency and granulation-promoting medicine. Species such as G. hanburyi and G. schefferi have been traditionally used as medicinal plants to treat human diseases in China, with these uses resulting from the exchange and sharing of traditional medicinal practices with people in Southeast Asia.

3. Key Constituents and Phytochemical Context

Garcinone C is one constituent within a rich xanthone profile in its source plants. The main phytochemicals present in Garcinia mangostana are isoprenylated xanthones, a class of secondary metabolites with multiple reports of biological effects, such as antioxidant, pro-apoptotic, anti-proliferative, antinociceptive, anti-inflammatory, neuroprotective, hypoglycemic and anti-obesity effects. Prenylated xanthones isolated from Garcinia mangostana have been extensively studied; some members of these compounds possess antioxidant, antitumoral, antiallergic, anti-inflammatory, antibacterial, antifungal and antiviral properties.

Unique to the mangosteen are a class of phytochemicals known as xanthones that have been reported to display significant anti-cancer and anti-tumor activities, specifically through the promotion of apoptosis, targeting of specific cancer-related proteins, or modulation of cell signaling pathways. α-Mangostin, the most abundant xanthone isolated from the mangosteen, has received substantial attention. Lesser xanthones, including gartanin, β-mangostin, γ-mangostin, garcinone C, and garcinone E, and mangosteen extracts from the pericarp, roots, rind, and stem show promise for their anticancer activity but their mechanisms of action are not as well developed and remain to be determined.

Garcinone C, which is the main natural phytochemical isolated from the fruit mangosteen, also possesses good antioxidant activity and is a derivative of the natural phenolic antioxidant lutein.

4. Mechanisms of Action

4.1 Cell Cycle Regulation and Anti-Proliferative Signaling

Several mechanistic pathways have been identified through which garcinone C exerts anti-proliferative effects. Garcinone C stimulates the expression levels of ATR and 4E-BP1, while efficiently inhibiting the expression levels of cyclin B1, cyclin D1, cyclin E2, cdc2, CDK7 and Stat3. These targets indicate interference with both cell cycle progression and the JAK/STAT3 signaling axis. Flow cytometry demonstrated that garcinone C arrested the cell cycle at the S phase in nasopharyngeal carcinoma cells, while in colon cancer cells, garcinone C suppressed the proliferation of colon cancer cells, induced G0/G1 cell cycle arrest, as well as regulated the expression of cell cycle-related markers such as cyclin D1, cyclin E, CDK6, and p21.

4.2 Hedgehog/Gli1 Signaling Pathway Inhibition

A mechanistically significant and recurring finding in multiple cancer types is garcinone C's modulation of the Hedgehog (Hh) signaling pathway. Garcinone C inhibited the expression of Gli1, a key mediator of Hedgehog signaling, and protein kinase B (AKT) phosphorylation in Smo-independent colon cancer cells. Computational studies have further characterized this interaction: garcinone C showed a high affinity with the Gli1 protein ZF domain by forming hydrogen bonds with amino acid residues of ASP244, ARG223, and ASP216. MG132 blocked the effects of garcinone C on Gli1, and thus garcinone C suppressed colorectal cancer stem-like cells (CSCs) by binding to Gli1 and enhancing its degradation.

4.3 NF-κB and Nrf2/HO-1 Pathway Modulation

In the context of bone metabolism, garcinone C has been shown to engage two interrelated signaling nodes. Treatment with garcinone C significantly increased bone mineral density and significantly decreased the expression of TRAP, NFATC1 and CTSK relative to untreated osteoporotic mice; garcinone C could disrupt osteoclast activation and resorption functions by inhibiting RANKL-induced osteoclast differentiation as well as inhibiting the formation of multinucleated osteoclasts. These results suggest that garcinone C significantly reduces OVX-induced osteoporosis by inhibiting osteoclast activation through oxidative stress, and this mechanism was associated with inhibition of the NF-κB pathway.

4.4 Acetylcholinesterase (AChE) Inhibition

Among six bioactive xanthones identified from G. mangostana pericarp — namely α-mangostin, γ-mangostin, mangostanol, 3-isomangostin, garcinone C and 8-deoxygartanin — the most potent inhibitor of AChE was garcinone C, while γ-mangostin was the most potent inhibitor of BChE. Acetylcholinesterase inhibition increases synaptic levels of acetylcholine and represents the primary pharmacological strategy behind FDA-approved cholinesterase inhibitor drugs for Alzheimer's disease, making this a mechanism of significant translational interest.

4.5 Neuroprotective Mechanisms

Xanthones including α-MG, γ-MG, gartanin, and garcinone C exhibited neuroprotective effects against glutamate-caused HT22 hippocampal neuronal cell death, partly by up-regulating HO-1 protein level. Additionally, these xanthones suppressed self-induced Aβ aggregation and β-secretase activity.

4.6 Antioxidant Properties

Garcinone C contributes to the antioxidant activity characteristic of mangosteen xanthones as a class. Earlier chemical studies on mangosteen pericarp revealed a series of xanthone derivatives, which showed antioxidant, anti-inflammatory, antifungal, and antitumor activities. The stress-repressing capacity of garcinone C and related xanthones was proposed to be directly correlated to their ability to scavenge oxygen peroxide.

5. Scientific Evidence by Area of Application

5.1 Oncology: Colorectal / Colon Cancer

This is the most thoroughly investigated cancer application for garcinone C. In research published in 2020, garcinone C suppressed the proliferation of colon cancer cells, induced G0/G1 cell cycle arrest, regulated cell cycle-related markers such as cyclin D1, cyclin E, CDK6, and p21, and inhibited the expression of Gli1 and AKT phosphorylation. In the AOM/DSS-induced colon tumorigenesis model in vivo, garcinone C significantly inhibited tumor development, regulated the expression of cell cycle markers and Gli1, and reduced AKT phosphorylation in colon tumor tissues. The conclusion of that study was that garcinone C can suppress colon tumorigenesis in vitro and in vivo through Gli1-dependent non-canonical Hedgehog signaling, suggesting that it may serve as a potent chemopreventive agent against colon tumorigenesis.

A subsequent study focused on colorectal cancer stem-like cells: garcinone C suppresses colorectal cancer in vivo and in vitro by inhibiting Gli1-dependent noncanonical hedgehog signaling. Gli1 was noted as pivotal in maintaining stemness and invasiveness in HCT116 and HT29 CSCs. Garcinone C inhibited the proliferation and self-renewal of HCT116 and HT29 CSCs. Colon cancer stemness markers such as CD44, CD133, ALDH1, and Nanog were significantly decreased by garcinone C. MMP2 and MMP9 levels, invasive-related markers, were increased in HCT116 CSCs but decreased by garcinone C. E-cadherin level was reduced in HCT116 CSCs, while the presence of garcinone C restored it.

Evidence level: Preclinical only (in vitro cell lines and in vivo mouse AOM/DSS model). No human clinical trials.

5.2 Oncology: Nasopharyngeal Carcinoma (NPC)

In a 2018 study, garcinone C significantly inhibited cell viability of the human NPC cell lines CNE1, CNE2, HK1 and HONE1, with inhibition exerted in a time- and dose-dependent manner. Flow cytometry demonstrated that garcinone C arrested the cell cycle at the S phase. Moreover, with 10 µM of high-dose garcinone C treatment, the cells exhibited necrotic morphology changes including cell swelling, rough endoplasmic reticulum degranulation, endoplasmic reticulum dilatation, mitochondrial swelling and vacuolar degeneration. Mechanistically, garcinone C stimulated the expression levels of ATR and 4E-BP1, while efficiently inhibiting the expression levels of cyclin B1, cyclin D1, cyclin E2, cdc2, CDK7 and Stat3.

Evidence level: In vitro only. No in vivo animal or human studies reported for NPC specifically.

5.3 Oncology: Prostate and Breast Cancer

Garcinone C significantly reduced the cell viability of 22RV1 prostate cancer cells and MDA-MB-231 breast cancer cells. Additionally, cytotoxicity has been documented against a panel of cancer cell lines: cytotoxicity was described against human breast carcinoma (MCF-7), human lung cancer (A549), human hepatoma (Hep-G2) and human carcinoma of nasopharynx (CNE) cell lines.

Evidence level: In vitro cell culture studies only. No clinical evidence.

5.4 Oncology: Gastric Cancer

A 2025 preprint (bioRxiv) reported that garcinone C suppressed the proliferation of gastric cancer cells through regulation of Hedgehog signaling, extending the Hh/Gli1 mechanistic axis to this cancer type. The effect of garcinone C on gastric cancer remains insufficiently explored, though findings underscore the potential of garcinone C as a candidate for further investigation in gastric cancer treatment.

Evidence level: Preliminary. Preclinical only; published as a preprint and not yet peer-reviewed in final form as of 2025.

5.5 Bone Health: Osteoporosis and Osteoclastogenesis

A 2024 study published in Heliyon investigated garcinone C in both cell-based and animal models of osteoporosis. Garcinone C could disrupt osteoclast activation and resorption functions by inhibiting RANKL-induced osteoclast differentiation as well as inhibiting the formation of multinucleated osteoclasts. Using an ovariectomy (OVX)-established osteoporosis mouse model, treatment with garcinone C significantly increased bone mineral density and significantly decreased the expression of TRAP, NFATC1 and CTSK relative to untreated OP mice. These results support garcinone C as a potential drug candidate for the treatment of osteoporosis.

Evidence level: Preclinical (in vitro osteoclast differentiation assays plus in vivo OVX mouse model). No human evidence.

5.6 Neuroprotection and Neurodegenerative Disease

Mangosteen pericarp and its xanthones may provide therapeutic advantages for Alzheimer's disease (AD), Parkinson's disease (PD), and depression. MP-derived agents have shown multifunctional effects including neuroprotective, antioxidant, and anti-neuroinflammatory actions. Specifically in relation to garcinone C, garcinone C exhibited neuroprotective effects against glutamate-caused HT22 hippocampal neuronal cell death, partly by up-regulating HO-1 protein level. The compound's cholinesterase inhibitory properties — with garcinone C identified as the most potent AChE inhibitor among tested xanthones — are mechanistically relevant to the cholinergic hypothesis of Alzheimer's disease. Xanthones as a class have shown potential neuroprotective effects in Alzheimer's disease due to their antioxidant, anti-inflammatory, and acetylcholinesterase inhibitory properties.

Garcinone C has a broad range of activities, including antioxidant and anti-cholinesterase activities, and it can pass through the blood-brain barrier and suppress self-induced β-amyloid aggregation. However, low oral bioavailability and poor brain penetration may limit the therapeutic applications of mangosteen-derived xanthones including garcinone C.

Evidence level: In vitro neuronal cell studies and mechanistic data. No clinical or animal model evidence specific to garcinone C for neurodegeneration.

5.7 Antimicrobial Activity: Anti-Leptospiral

A study examined the inhibitory activity of purified xanthones and crude extracts from Garcinia mangostana against both non-pathogenic and pathogenic leptospira. Among the crude extracts and purified xanthones, garcinone C was the most active compound against both pathogenic (MIC = 100 µg/ml) and non-pathogenic leptospira (MIC = 200 µg/ml). However, these MIC values were higher than those of traditional antibiotics. The study authors compared garcinone C's activity to standard agents and noted that the lowest MIC of all test xanthones against 5 leptospire serovars was 100 µg/ml, which is basically higher than traditional antibiotics for the treatment of leptospirosis such as penicillin G.

Evidence level: In vitro microbiological study. No in vivo or clinical data for anti-leptospiral use.

5.8 Anti-inflammatory Activity

The medicinal value of mangosteen pericarp is primarily attributed to its abundance of xanthones, especially prenylated derivatives, which exhibit diverse pharmacological applications such as anti-inflammatory, antioxidant, anticancer, antimicrobial, antifungal, and antiviral activities. Within the pericarp xanthone fraction, γ-mangostin, garcinone D, and other isolated components showed the most potent NO-inhibitory effects in LPS-stimulated RAW264.7 cells. SAR study revealed that chromeno moiety at C-3,4, oxygen substituents at C-1,3,6,7, and isoprenyl groups at C-2,8 are key structural features that promoted anti-inflammatory activity. Garcinone C shares the oxygen substitution pattern at C-1,3,6,7 that is identified as a key structural driver of anti-inflammatory activity.

Evidence level: In vitro. No clinical evidence specific to garcinone C as an anti-inflammatory agent in isolation.

5.9 Antioxidant Activity

Garcinone C possesses good antioxidant activity. Mangosteen is known for its antioxidant, anti-inflammatory, and anticancer activities. Antioxidant properties of garcinone C have been evaluated using standard assays (e.g., DPPH radical scavenging) in multiple phytochemical screening studies, consistently demonstrating activity, though typically at lower potency than the more abundant α-mangostin. The antioxidant mechanism has been linked to the compound's capacity to activate the Nrf2/HO-1 cytoprotective axis, as demonstrated in the osteoclast differentiation studies described above.

Evidence level: In vitro. No human studies specific to garcinone C's antioxidant capacity.

6. Body Systems and Health Areas of Association

• Oncology / Cell biology: Colorectal, nasopharyngeal, prostate, breast, hepatoma, lung, and gastric cancer cell lines; cancer stem cell biology.
• Musculoskeletal system: Osteoclast differentiation, bone mineral density, and osteoporosis (RANKL/NF-κB pathway).
• Nervous system: Acetylcholinesterase inhibition, neuroprotection against glutamate and β-amyloid toxicity, HO-1 upregulation in hippocampal neurons.
• Immune and inflammatory system: NF-κB pathway suppression, nitric oxide modulation.
• Antimicrobial: Documented activity against Leptospira species in vitro.
• Redox biology: Antioxidant (ROS scavenging, Nrf2/HO-1 pathway activation).

7. Concentrations and Dosages Reported in Studies

No human clinical trials for garcinone C as an isolated compound have been published. The following concentrations and doses are drawn from preclinical studies only and are not recommendations.

• Nasopharyngeal carcinoma (in vitro, 2018): With 10 µM of high-dose garcinone C treatment, the cells exhibited necrotic morphology changes. Inhibitory effects on cell viability were demonstrated across a range of sub-micromolar to micromolar concentrations in a time- and dose-dependent manner.
• Anti-leptospiral (in vitro, 2013): Garcinone C was the most active compound against pathogenic leptospira at MIC = 100 µg/ml and non-pathogenic leptospira at MIC = 200 µg/ml.
• Osteoporosis (in vivo, OVX mouse model, 2024): Garcinone C was orally administered in an OVX mouse model (using an OP mouse model established by ovariectomy [OVX], treatment with garcinone C significantly increased bone mineral density); specific mg/kg dosage was not reported in the available extracts.
• Colorectal cancer in vitro and in vivo (2020): In the AOM/DSS-induced colon tumorigenesis model, garcinone C significantly inhibited tumor development via oral administration. Specific dosage in mg/kg was not retrievable from available abstracts.

For context on the whole-fruit matrix, in a human bioavailability study, healthy adults ingested a single dose (60 mL) of mangosteen juice containing 130 mg of xanthones. The proportion attributable specifically to garcinone C within this total xanthone dose was not reported.

8. Pharmacokinetics and Bioavailability

Pharmacokinetic studies specific to garcinone C as an isolated compound are limited. The broader pharmacokinetic behavior of mangosteen xanthones is informative: both free and glucuronidated/sulfated xanthones were detected in serum and urine following ingestion of mangosteen juice. Variability in maximum concentration of α-MG in serum (113 ± 107 nmol/L) and in time to maximum concentration (3.7 ± 2.4 h) was noted for 10 subjects. Urinary excretion of xanthones accounted for 2% of the ingested dose. Xanthones were still present in plasma 24 hours after juice ingestion, suggesting slow turnover.

A significant limitation for garcinone C and related xanthones is bioavailability. Their therapeutic use is limited by low bioavailability and restricted blood-brain barrier (BBB) penetration. Garcinone C's capacity to cross the blood-brain barrier has been suggested based on its structural features and has been cited in the context of its AChE inhibitory and neuroprotective potential, though this has not been confirmed in human pharmacokinetic studies.

9. Safety Considerations

9.1 General Safety Profile

Dedicated formal safety and toxicology studies for isolated garcinone C have not been published as of the current literature. What is known about the safety of mangosteen pericarp extracts as a whole matrix provides indirect contextual information. Mangosteen pericarp and its xanthones have been discussed for their pharmacokinetic and safety profiles in the context of neurodegenerative disease. The xanthone-rich pericarp extract has been consumed widely in beverage form without reports of significant acute toxicity in clinical studies.

9.2 Cytotoxic Concentration Considerations

At high doses in cell culture, garcinone C demonstrates frank cytotoxicity. With 10 µM of high-dose garcinone C treatment, the cells exhibited necrotic morphology changes including cell swelling, rough endoplasmic reticulum degranulation, endoplasmic reticulum dilatation, mitochondrial swelling and vacuolar degeneration. This indicates that the compound, at sufficiently high concentrations, may be cytotoxic in a non-selective manner, a consideration relevant to extrapolating in vitro anticancer findings.

9.3 Bioavailability as a Limitation and Safety Factor

Low oral bioavailability and poor brain penetration may limit the therapeutic applications of mangosteen-derived xanthones. This same characteristic means that achieving systemically significant concentrations of garcinone C from oral consumption of mangosteen preparations would require substantial amounts of raw material, the safety implications of which at high concentrations have not been formally studied.

9.4 Absence of Clinical Interaction Data

No published human clinical trials or formal pharmacokinetic interaction studies involving garcinone C as an isolated substance have been identified. The broader literature on mangosteen xanthones does not include systematic investigation of drug-drug interactions for garcinone C specifically. The compound's mechanism of action on multiple signaling pathways — including Stat3, NF-κB, cyclin-dependent kinases, and AKT — suggests that its potential pharmacological interactions at therapeutic concentrations would be complex if it ever reached clinical development, though this remains speculative in the absence of clinical data.

9.5 Evidence Gap

It is important to state plainly that sales of mangosteen-containing beverages in the USA alone exceeded $200 million in 2008 despite very limited animal and human studies. The biological activities documented for garcinone C — including its anticancer, neuroprotective, anti-osteoporotic, and antimicrobial effects — are currently supported exclusively by in vitro cell culture studies and, in a small number of cases, animal model experiments. No controlled human clinical trials have been published for garcinone C as an isolated compound. The diversity of actions displayed by mangosteen xanthones shows that these compounds target multiple signaling pathways involved in different pathologies, and place them as valuable sources for developing new drugs to treat chronic and degenerative diseases, but this potential has not yet been validated in human subjects for garcinone C.

References

• Iinuma M et al. The structures of garcinones a, b and c: Three new xanthones from Garcinia mangostana. Phytochemistry, 1982. ScienceDirect.
• Garcinone C | C23H26O7 | CID 44159808 – PubChem (NIH)
• Xia Y et al. Garcinone C exerts antitumor activity by modulating the expression of ATR/Stat3/4E-BP1 in nasopharyngeal carcinoma cells. Oncology Reports, 2018.
• Chen J et al. Garcinone C suppresses colon tumorigenesis through the Gli1-dependent hedgehog signaling pathway. Phytomedicine, 2020. PubMed.
• Zhou Y et al. Garcinone C Suppresses Tumorsphere Formation and Invasiveness by Hedgehog/Gli1 Signaling in Colorectal Cancer Stem-like Cells. Journal of Agricultural and Food Chemistry, 2022. ACS Publications.
• Garcinone C suppressed the proliferation of gastric cancer cells through regulating Hedgehog signaling. bioRxiv preprint, 2025.
• Ji H et al. Garcinone C attenuates RANKL-induced osteoclast differentiation and oxidative stress by activating Nrf2/HO-1 and inhibiting the NF-κB signaling pathway. Heliyon, 2024. PMC.
• LC-QTOF-MS analysis of xanthone content in different parts of Garcinia mangostana and its influence on cholinesterase inhibition. PMC, 2020.
• Do HTT, Cho J. Mangosteen Pericarp and Its Bioactive Xanthones: Potential Therapeutic Value in Alzheimer's Disease, Parkinson's Disease, and Depression with Pharmacokinetic and Safety Profiles. International Journal of Molecular Sciences, 2020. MDPI.
• Antilopiral activity of xanthones from Garcinia mangostana and synergy of gamma-mangostin with penicillin G. BMC Complementary Medicine and Therapies, 2013. PMC.
• Pedraza-Chaverri J et al. Medicinal properties of mangosteen (Garcinia mangostana L.): A comprehensive update. Food and Chemical Toxicology, 2017. ScienceDirect.
• Obolskiy D et al. Medicinal properties of mangosteen (Garcinia mangostana). Phytotherapy Research, 2009. PubMed.
• Garcinoxanthones SV, new xanthone derivatives from the pericarps of Garcinia mangostana. Fitoterapia, 2021. ScienceDirect.
• Garcixanthones B and C, new xanthones from the pericarps of Garcinia mangostana and their cytotoxic activity. Chinese Journal of Natural Medicines, 2018. ScienceDirect.
• Ovalle-Magallanes B et al. Biological Activities and Bioavailability of Mangosteen Xanthones: A Critical Review of the Current Evidence. Nutrients, 2013. PMC.
• Insights into Bioactive Constituents from Pericarp of Garcinia mangostana: Anti-Inflammatory Effects via NF-κB/MAPK Modulation and M1/M2 Macrophage Polarization. PMC, 2025.
• Fu M et al. A New Xanthone from the Pericarp of Garcinia mangostana. Natural Product Communications, 2013. SAGE Journals.
• Inhibition and potential treatment of colorectal cancer by natural compounds via various signaling pathways. Frontiers in Oncology, 2022.
• Alzheimer's disease: unraveling role of xanthone derivatives and nanocarriers. Naunyn-Schmiedeberg's Archives of Pharmacology, 2026. Springer.